Cite
HARVARD Citation
Kim, J. et al. (2018). Estimation of cost savings between 2011 and 2014 attributed to infliximab biosimilar in the South Korean healthcare market: real‐world evidence using a nationwide database. International journal of rheumatic diseases. pp. 1227-1236. [Online].